![Maria Patrizia Caldirola](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Maria Patrizia Caldirola
Chief Executive Officer at ClanoTech AB
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Yihai Cao | M | - |
ClanoTech AB
![]() ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | 18 years |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
Sweden | 1 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Maria Patrizia Caldirola
- Personal Network